Stock Evaluator: BioLineRx Ltd. (BLRX)

BioLineRx Ltd. BLRX

$1.79 -0.07 -3.76%
November 5, 2026 12:32:44 PM EST November 10, 2021 Volume: 12,667
After Hours: $120.37   0.15  |  0.12% November 10, 2021 7:59 PM EST Volume: 72,713
USD NASD | DELAYED PRICE
SECTOR INDUSTRY
Health Care Biotechnology

A+ Stock Grade Summary:

VALUE:
GROWTH:
MOMENTUM:
EPS REVISIONS:
QUALITY:
COMPANY SUMMARY
BioLineRx Ltd., a biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company’s pipeline includes GLIX1, an oral, small molecule targeting DNA damage response in glioblastoma and other cancers; and APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma. It develops BL-5010, a pen-like applicator containing an acidic aqueous solution for the non-surgical removal of skin lesions. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.

Commentary & Analysis


Financial Summary

Share Statistics BLRX Industry
Median
Percentile
(All Stocks)
Market Cap (Mil) $9.4 $227.3 7%
Shares Out (Mil) 2,664.8 53.4 98%
Institutional Ownership 79.6% 92.9% 49%
Float (Mil) 2,829.9 41.4 97%
Beta 0.70 0.95 40%
Avg Daily Volume (000s) 6 468 15%
Price Change
(52-week)
(46.4%) 47.4% 21%
Growth BLRX Industry
Median
Percentile
(All Stocks)
Sales (5yr) na 13.2% na
Net Income (5yr) 47.5% (10.1%) 93%
EPS (5yr) 14.9% 15.8% 56
Dividends (5yr) na 0.0% 0%
Cash Flow (5yr) (14.9%) (15.7%) 53%
Estimates Qtrly Current
Fiscal
Year
Next
Fiscal
Year
# of Estimates na 1 1
Current EPS $0.000 ($3.140) ($2.520)
Month Ago EPS na ($3.140) ($2.520)
# Rev Up 0 0 1
# Rev Down 1 1 0
Three Months Ago EPS na na na
Year/Year Chg (100.0%) na na
Financials BLRX Industry
Median
Percentile
(All Stocks)
Sales (TTM) (Mil) $1 $37 2%
Net Income (TTM) (Mil) ($7) ($44) 31%
EPS (TTM) ($0.003) ($1.600) 38%
Operating Cash Flow (TTM) (Mil) ($11) ($34) 20%
Net Cash Flow (TTM) (Mil) ($3) $1 37%
Long-Term Debt (Q1) (Mil) $3 $4 22%
Enterprise Value (Q1) (Mil) $10 $174 8%
Valuation BLRX Industry
Median
Percentile
(All Stocks)
P/B 186.00 2.14 100%
P/E na 20.6 na
Dividend Yield 0.0% 0.0% 0%
PEG (5yr hist) na 1.1 na
Ratios BLRX Industry
Median
Percentile
(All Stocks)
Gross Margin 80.0% 66.5% 89%
Net Margin (502.1%) (69.8%) 2%
ROA (18.2%) (47.1%) 21%
ROE (41.3%) (52.0%) 17%
Liabilities to Assets 50.4% 29.7% 43%
F-Score 2 2 7%

BioLineRx Ltd. did not pass any screens on 11/4/2026.

Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.

Ⓒ 2026 American Association of Individual Investors